|Incidence: ||46,420 (male: 23,530; female: 22,890. Estimated new cases for 2014 in the United States) ||Stage at presentation: |
|(13.9 per 100,000 males; 10.9 per 100,000 females) ||Stage I: ||20% |
|Deaths: ||Estimated 39,590 in 2014 (male: 20,170; female: 19,420) ||Stage II: ||40% |
|Median age: ||71 years ||Stage III–IV: ||40% |
|Male to female ratio: ||~1:1 |
Siegel R et al. CA Cancer J Clin 2014;64:9–29
Surveillance, Epidemiology, and End Results (SEER) Program, available from http://seer.cancer.gov (accessed in 2013)
Takhar AS et al. BMJ 2004;329:668–673
Most cancers of the pancreas arise in the head of the pancreas (60–70%), 15% in the body, and 5% in the tail; in 20%, the neoplasm diffusely involves the entire gland
|Malignant Tumors of Pancreatic Origin |
|Ductal adenocarcinoma ||85–90% |
|Acinar cell carcinoma ||1–2% |
|Undifferentiated carcinoma (anaplastic giant cell, osteoclastic giant cell) ||<1% |
|Sarcomatoid carcinoma/carcinosarcoma ||<1% |
de Braud F et al. Crit Rev Oncol Hematol 2004;50: 147–155
Solcia E et al. Tumors of the pancreas. In: Atlas of Tumor Pathology, 3rd series. Washington, DC: Armed Forces Institute; 1997
The diagnosis of pancreatic cancer is based on imaging studies and histologic confirmation performed by fine-needle aspiration by endoscopic ultrasonography (EUS), biopsy under CT or US guidance, or during laparotomy
History and physical examination
CBC and differential, serum electrolytes, creatinine, LFTs, PT, PTT, CA19-9
Spiral CT: Spiral or a helical CT of the abdomen according to a defined pancreatic protocol is essential. CT provides localization, size of the primary tumor, and evidence of metastasis and evaluates major vessels adjacent to the pancreas for neoplastic invasion or thrombosis. CT is almost 100% accurate in predicting unresectable disease. However, the positive predictive value of the test is low and approximately 25–50% of patients predicted to have resectable disease on CT turn out to have unresectable lesions at laparotomy
Endoscopic retrograde cholangiopancreatography (ERCP) can also be useful in patients whom a CT scan is equivocal, because fewer than 3% of patients with pancreatic carcinoma have normal pancreatograms
EUS is a relatively new technique and provides useful information. However, EUS needs to be performed in centers with experience in this procedure. EUS is useful for characterizing cystic lesions and assessment of vascular invasion by tumor. In addition, an aspirate can be done for histologic diagnosis. A celiac plexus block can be done via EUS for relief of abdominal pain
Agawam B. Am J Gastroenterol 2004;99:844–850
Tamm EP et al. Radiographic Imaging: Daniel D. Von Hoff, Douglas B. Evans, Ralph H. Hruban, eds. Pancreatic Cancer, 1st ed. Jones & Bartlett Publishers, 2005:165–180
|Primary Tumor (T)|
|TX ||Primary tumor cannot be assessed |
|T0 ||No evidence of primary tumor |
|Tis ||Carcinoma in situ |
|T1 ||Tumor limited to the pancreas, 2 cm or ...|
Log In to View More
If your institution is currently a subscriber
of the HemOnc Collection please sign in below.
If your institution is not a subscriber
please click here
to learn more.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.